Works by Kimura, Yoshihide


Results: 20
    1

    Poor Tolerability of Lenvatinib in Elderly Patients with Advanced Hepatocellular Carcinoma after Disease Progression following First-Line Atezolizumab Plus Bevacizumab: A Multicenter Study.

    Published in:
    Oncology, 2025, v. 103, n. 4, p. 311, doi. 10.1159/000541455
    By:
    • Kato, Daisuke;
    • Suzuki, Takanori;
    • Matsuura, Kentaro;
    • Okayama, Kohei;
    • Okumura, Fumihiro;
    • Nagura, Yoshihito;
    • Sobue, Satoshi;
    • Hayashi, Katsumi;
    • Kusakabe, Atsunori;
    • Hasegawa, Izumi;
    • Matoya, Sho;
    • Mizoshita, Tsutomu;
    • Kimura, Yoshihide;
    • Kondo, Hiromu;
    • Ozasa, Atsushi;
    • Kawamura, Hayato;
    • Fujiwara, Kei;
    • Nojiri, Shunsuke;
    • Kataoka, Hiromi
    Publication type:
    Article
    2

    Prognostic Nutritional Index after Introduction of Atezolizumab with Bevacizumab Predicts Prognosis in Advanced Hepatocellular Carcinoma: A Multicenter Study.

    Published in:
    Oncology, 2024, v. 102, n. 8, p. 676, doi. 10.1159/000536367
    By:
    • Suzuki, Takanori;
    • Matsuura, Kentaro;
    • Suzuki, Yuta;
    • Okumura, Fumihiro;
    • Nagura, Yoshihito;
    • Sobue, Satoshi;
    • Kato, Daisuke;
    • Kusakabe, Atsunori;
    • Koguchi, Hiroki;
    • Hasegawa, Izumi;
    • Matoya, Sho;
    • Miyaki, Tomokatsu;
    • Kimura, Yoshihide;
    • Tanaka, Yoshito;
    • Kondo, Hiromu;
    • Ozasa, Atsushi;
    • Kawamura, Hayato;
    • Kuno, Kayoko;
    • Fujiwara, Kei;
    • Nojiri, Shunsuke
    Publication type:
    Article
    3
    4
    5
    6
    7

    Adalimumab Dose-Escalation Therapy Is Effective in Refractory Crohn's Disease Patients with Loss of Response to Adalimumab, Especially in Cases without Previous Infliximab Treatment.

    Published in:
    Case Reports in Gastroenterology, 2019, v. 13, n. 1, p. 37, doi. 10.1159/000496453
    By:
    • Suzuki, Taketo;
    • Mizoshita, Tsutomu;
    • Sugiyama, Tomoya;
    • Hirata, Yoshikazu;
    • Kimura, Yoshihide;
    • Suzuki, Yuka;
    • Yamada, Tomonori;
    • Tsukamoto, Hironobu;
    • Mizushima, Takashi;
    • Sugimura, Naomi;
    • Katano, Takahito;
    • Tanida, Satoshi;
    • Kataoka, Hiromi;
    • Sasaki, Makoto
    Publication type:
    Article
    8
    9

    Serum interleukin‐6 levels at the start of the second course of atezolizumab plus bevacizumab therapy predict therapeutic efficacy in patients with advanced hepatocellular carcinoma: a multicenter analysis.

    Published in:
    Journal of Gastroenterology & Hepatology, 2024, v. 39, n. 10, p. 2158, doi. 10.1111/jgh.16672
    By:
    • Suzuki, Takanori;
    • Matsuura, Kentaro;
    • Suzuki, Yuta;
    • Okumura, Fumihiro;
    • Nagura, Yoshihito;
    • Sobue, Satoshi;
    • Matoya, Sho;
    • Miyaki, Tomokatsu;
    • Kimura, Yoshihide;
    • Kusakabe, Atsunori;
    • Narahara, Satoshi;
    • Tokunaga, Takayuki;
    • Nagaoka, Katsuya;
    • Murakami, Shuko;
    • Inoue, Takako;
    • Kuroyanagi, Keita;
    • Kawamura, Hayato;
    • Fujiwara, Kei;
    • Nojiri, Shunsuke;
    • Kataoka, Hiromi
    Publication type:
    Article
    10
    11
    12

    Serum CXCL10 levels at the start of the second course of atezolizumab plus bevacizumab therapy predict therapeutic efficacy in patients with advanced BCLC stage C hepatocellular carcinoma: A multicenter analysis.

    Published in:
    Cancer Medicine, 2024, v. 13, n. 1, p. 1, doi. 10.1002/cam4.6876
    By:
    • Takanori Suzuki;
    • Kentaro Matsuura;
    • Yuta Suzuki;
    • Fumihiro Okumura;
    • Yoshihito Nagura;
    • Satoshi Sobue;
    • Sho Matoya;
    • Tomokatsu Miyaki;
    • Yoshihide Kimura;
    • Atsunori Kusakabe;
    • Satoshi Narahara;
    • Takayuki Tokunaga;
    • Katsuya Nagaoka;
    • Keita Kuroyanagi;
    • Hayato Kawamura;
    • Kayoko Kuno;
    • Kei Fujiwara;
    • Shunsuke Nojiri;
    • Hiromi Kataoka;
    • Yasuhito Tanaka
    Publication type:
    Article
    13

    Neutrophil‐to‐lymphocyte ratio at the start of the second course of durvalumab plus tremelimumab therapy predicts therapeutic efficacy in patients with advanced hepatocellular carcinoma: A multicenter analysis.

    Published in:
    Hepatology Research, 2025, v. 55, n. 6, p. 883, doi. 10.1111/hepr.14189
    By:
    • Suzuki, Takanori;
    • Matsuura, Kentaro;
    • Sobue, Satoshi;
    • Kato, Daisuke;
    • Hayashi, Katsumi;
    • Kondo, Hiromu;
    • Anbe, Kaiki;
    • Mizoshita, Tsutomu;
    • Okayama, Kohei;
    • Okumura, Fumihiro;
    • Kimura, Yoshihide;
    • Ozasa, Atsushi;
    • Inada, Hiroki;
    • Tokunaga, Takayuki;
    • Narahara, Satoshi;
    • Kawamura, Hayato;
    • Fujiwara, Kei;
    • Nojiri, Shunsuke;
    • Kataoka, Hiromi;
    • Tanaka, Yasuhito
    Publication type:
    Article
    14

    The neutrophil‐to‐lymphocyte ratio at the start of the second course during atezolizumab plus bevacizumab therapy predicts therapeutic efficacy in patients with advanced hepatocellular carcinoma: A multicenter analysis.

    Published in:
    Hepatology Research, 2023, v. 53, n. 6, p. 511, doi. 10.1111/hepr.13886
    By:
    • Matoya, Sho;
    • Suzuki, Takanori;
    • Matsuura, Kentaro;
    • Suzuki, Yuta;
    • Okumura, Fumihiro;
    • Nagura, Yoshihito;
    • Sobue, Satoshi;
    • Kuroyanagi, Keita;
    • Kusakabe, Atsunori;
    • Koguchi, Hiroki;
    • Hasegawa, Izumi;
    • Miyaki, Tomokatsu;
    • Tanaka, Yoshito;
    • Kondo, Hiromu;
    • Kimura, Yoshihide;
    • Ozasa, Atsushi;
    • Kawamura, Hayato;
    • Kuno, Kayoko;
    • Fujiwara, Kei;
    • Nojiri, Shunsuke
    Publication type:
    Article
    15

    Outcome of nucleos(t)ide analog cessation in patients with treatment for prevention of or against hepatitis B virus reactivation.

    Published in:
    Hepatology Research, 2023, v. 53, n. 4, p. 289, doi. 10.1111/hepr.13864
    By:
    • Suzuki, Takanori;
    • Matsuura, Kentaro;
    • Urakabe, Kenji;
    • Okumura, Fumihiro;
    • Kawamura, Hayato;
    • Sobue, Satoshi;
    • Matoya, Sho;
    • Miyaki, Tomokatsu;
    • Kimura, Yoshihide;
    • Kato, Daisuke;
    • Kusakabe, Atsunori;
    • Tanaka, Yoshito;
    • Ozasa, Atsushi;
    • Nagura, Yoshihito;
    • Fujiwara, Kei;
    • Nojiri, Shunsuke;
    • Hagiwara, Shinya;
    • Kusumoto, Shigeru;
    • Inoue, Takako;
    • Tanaka, Yasuhito
    Publication type:
    Article
    16

    Efficacy of minocycline hydrochloride aspiration sclerotherapy with additional monoethanolamine oleate aspiration sclerotherapy for symptomatic hepatic cysts.

    Published in:
    Hepatology Research, 2023, v. 53, n. 3, p. 267, doi. 10.1111/hepr.13865
    By:
    • Kimura, Yoshihide;
    • Fujiwara, Kei;
    • Matsuura, Kentaro;
    • Suzuki, Takanori;
    • Senoo, Kyouji;
    • Tsuchida, Kenji;
    • Mori, Yoshinori;
    • Hirano, Atsuyuki;
    • Nomura, Satoshi;
    • Kitagawa, Mika;
    • Tomita, Yusaku;
    • Kanaiwa, Hiroki;
    • Imazu, Mitsuki;
    • Nagura, Yoshihito;
    • Nojiri, Shunsuke;
    • Kataoka, Hiromi
    Publication type:
    Article
    17

    Coexpression of organic anion-transporting polypeptides 1B3 and multidrug-resistant proteins 2 increases the enhancement effect of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid on hepatocellular carcinoma in magnetic resonance imaging.

    Published in:
    Hepatology Research, 2014, v. 44, n. 3, p. 327, doi. 10.1111/hepr.12128
    By:
    • Kimura, Yoshihide;
    • Sato, Shinya;
    • Hitomi, Eiichi;
    • Ohyama, Makoto;
    • Adachi, Kazunori;
    • Inagaki, Yusuke;
    • Yamakawa, Yoshihiro;
    • Hirano, Atsuyuki;
    • Kawai, Hiroki;
    • Tsuchida, Kenji;
    • Senoo, Kyouji;
    • Katsumi, Kohei;
    • Joh, Takashi
    Publication type:
    Article
    18
    19
    20